1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
EZZ Life Science Holdings Limited

EZZ Life Science Holdings Limited

EZZ.AX
EZZ Life Science Holdings LimitedAU flagAustralian Securities Exchange
0.59
AUD
-0.02
- -
27.52MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
0.66
0.35
0.87
1.54
1.45
Basic EPS, GAAP
- -
0.06
0.03
0.08
0.16
0.15
Free Cash Flow per Basic Share
- -
- -
- -
- -
-0.01
-0.01
Dividend per Share
- -
- -
- -
0.01
0.03
0.04
Book Value per Share
- -
0.3
0.27
0.34
0.49
0.61
Tangible Book Value per Share
- -
0.3
0.27
0.34
0.49
0.61
Basic Weighted Avg Shares
- -
34
43
43
43
46
Sales/Revenue/Turnover
- -
22
15
37
66
67
Operating Margin (%)
- -
11.54
10.93
12.43
14.62
14.85
Depreciation Expense
- -
- -
- -
- -
- -
1
Net Income, GAAP
- -
2
1
4
7
7
Effective Tax Rate (%)
- -
25.8
26.26
25.93
30.07
36.42
Profit Margin (%)
- -
9.11
8.74
9.77
10.48
10.06
Working Capital
8
10
11
14
21
27
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
8
10
11
15
21
28
Return on Invested Capital (%)
- -
20.33
10.96
25.24
35.8
24.07
Return on Capital (%)
- -
22.56
12.14
27.4
38.27
27.05
Return on Common Equity (%)
- -
22.61
12.21
27.95
38.81
27.27

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
29.47%
31.71%
Free Cash Flow
- -
- -
-36.26%
Net Income, GAAP
- -
- -
-3.36%
Sales/Revenue/Turnover
- -
- -
0.65%
Total Cash Common Dividend
- -
- -
67.96%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
37
2024
- -
- -
- -
- -
66
2025
- -
- -
- -
- -
67

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.08
2024
- -
- -
- -
- -
0.16
2025
- -
- -
- -
- -
0.15

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.04

Company Description

APIChat
CEO
Mark Qin
Full Time Employees
11
Sector
Healthcare
Industry
Biotechnology
Address
104 Derby Street Lidcombe NSW Australia 2128
IPO Date
Mar 2, 2021
Website
ezzlife.com.au
Similar Companies
Biotron Limited (BITRF)
Diffusion Pharmaceuticals Inc. (DFFN)
9 Meters Biopharma, Inc. (NMTRQ)
Shanghai Shen Lian Biomedical Corporation (688098.SS)
Big Cypress Acquisition Corp. (BCYPU)
60 Degrees Pharmaceuticals, Inc. (SXTP)
Business
EZZ Life Science Holdings Limited (ASX:EZZ) is an Australian genomic life sciences company that formulates, produces, markets and sells EZZ-branded health and wellbeing products to retailers and consumers; and acts as the exclusive distributor of EAORON-branded premium skincare solutions, including facial care items, in Australia and New Zealand. The EZZ portfolio encompasses science-backed supplements addressing genomic research priorities such as genetic longevity, human papillomavirus, helicobacter pylori, children's health and weight management; specific products include EZZ Hair Growth Spray Duo, EZZ Multi Vitamins Milk Powder for Children (ages three plus), EZZ KidzSure Formulated Nutrition Powder (ages three plus), EZZ VitalSure Formulated Nutrition Powder for adults, vitamins, dietary supplements, sports nutrition, herbal remedies and precision nutrition offerings. Founded in 2015 and headquartered at Shop 1, 55-59 Parramatta Road, Lidcombe, New South Wales, the company operates through Company Owned Products and Brought in Lines segments via omnichannel models in Australia, New Zealand, mainland China, South-East Asia and other international markets. Recent developments include a three-year non-exclusive distribution agreement with ROFA Enterprises in June 2025 to distribute at least $21 million of EZZ-branded products across Thailand, Vietnam and Singapore; a manufacturing partnership with GLSP Inc to produce EZZ nutrition supplements in the United States for North American expansion; issuance of 1,735,000 ordinary fully paid securities in October 2024; and declaration of a fully franked final dividend of $0.020 per share for the financial year ending 30 June 2025.